NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy

Arne Trummer, Andre Bethge,Nicolas Dickgreber, Ina Dittrich,Heiko Golpon,Petra Hoffknecht, Tobias R. Overbeck,Claas Wesseler, Martin Reck

Lung Cancer（2022）

引用 3|浏览8

暂无评分

摘要

•Atezolizumab, Bevacizumab, Carboplatin and (nab-)Paclitaxel demonstrates high efficacy and moderate toxicity in uncommon EGFR mutations.•Outcome is independent of type of mutation, smoking status, PD-L1 expression and prior TKI treatment.•Amivantamab remains a treatment option for Exon 20 insertions after ABCP.

查看译文

关键词

Non-small cell lung cancer,Uncommon EGFR mutation,Exon 20 insertion,Quadruple therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要